What is Zacks Research’s Forecast for IQVIA FY2025 Earnings?

IQVIA Holdings Inc. (NYSE:IQV) – Investment analysts at Zacks Research lifted their FY2025 earnings per share estimates for IQVIA in a report released on Monday, November 17th. Zacks Research analyst Team now anticipates that the medical research company will earn $10.71 per share for the year, up from their prior estimate of $10.59. The consensus estimate for IQVIA’s current full-year earnings is $10.84 per share. Zacks Research also issued estimates for IQVIA’s Q1 2026 earnings at $2.61 EPS, Q2 2026 earnings at $2.73 EPS, Q3 2026 earnings at $2.92 EPS, Q4 2026 earnings at $3.33 EPS, FY2026 earnings at $11.57 EPS, Q1 2027 earnings at $2.90 EPS, Q2 2027 earnings at $3.14 EPS and FY2027 earnings at $12.96 EPS.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the previous year, the firm posted $2.84 earnings per share. IQVIA’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS.

Other analysts have also issued reports about the stock. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Mizuho boosted their target price on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Redburn Partners set a $214.00 target price on IQVIA in a report on Wednesday, September 3rd. Finally, Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $240.61.

IQVIA Price Performance

Shares of NYSE IQV opened at $217.50 on Thursday. The firm has a 50-day moving average of $204.51 and a two-hundred day moving average of $180.05. The company has a market capitalization of $37.04 billion, a price-to-earnings ratio of 29.84, a PEG ratio of 2.44 and a beta of 1.34. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA has a twelve month low of $134.65 and a twelve month high of $228.12.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Physician Wealth Advisors Inc. grew its position in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the period. Westside Investment Management Inc. grew its holdings in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new position in IQVIA in the 3rd quarter worth approximately $30,000. Finally, Atlantic Union Bankshares Corp acquired a new position in shares of IQVIA during the third quarter worth approximately $36,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.